New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

"While these results must be treated with caution, the analysis shows semaglutide can be an effective tool to treat this advanced liver disease," said lead researcher Professor Philip Newsome ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

9 patients died—3 in the semaglutide group and 6 in the placebo group—though there was no evident clustering of cause of death, according to the authors. Average bodily pain scores were not ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal ...

“While these results must be treated with caution, the analysis shows semaglutide can be an effective tool to treat this advanced liver disease,” said lead researcher Professor Philip ...